PR001

Migration, Crosslink

📖

PR001

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-pr001

📖 Wiki Page

entity2990 wordssynced 2026-04-02

PR001 is an AAV gene therapy candidate developed by [Prevail Therapeutics](https://prevailtherapeutics.com) (an Eli Lilly company) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) patients with GBA1 mutations (GBA-PD)[@prevail2024]. This experimental gene therapy delivers a functional copy of the [GBA1](/genes/gba1) gene to restore glucocerebrosidase (GCase) activity, targeting the root cause of lysosomal dysfunction in [synucleinopathies](/mechanisms/synucleinopathies)[@schapira2022].

Mechanism of Action

...

PR001 is an AAV gene therapy candidate developed by [Prevail Therapeutics](https://prevailtherapeutics.com) (an Eli Lilly company) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) patients with GBA1 mutations (GBA-PD)[@prevail2024]. This experimental gene therapy delivers a functional copy of the [GBA1](/genes/gba1) gene to restore glucocerebrosidase (GCase) activity, targeting the root cause of lysosomal dysfunction in [synucleinopathies](/mechanisms/synucleinopathies)[@schapira2022].

Mechanism of Action

Mermaid diagram (expand to render)

PR001 delivers a functional copy of the GBA1 gene via AAV9 vector directly to the brain, enabling long-term expression of functional [glucocerebrosidase](/entities/glucocerebrosidase) (GCase) in neurons and astrocytes["@sardi2021"]. The therapeutic rationale includes:

Restores glucocerebrosidase enzyme activity to reduce [glucosylceramide](/entities/glucosylceramide) accumulation
Improves [lysosomal](/mechanisms/lysosomal-dysfunction) function and [autophagy](/mechanisms/autophagy) flux
May reduce [alpha-synuclein](/proteins/alpha-synuclein) accumulation and propagation in [dopaminergic neurons](/cell-types/dopaminergic-neurons)
Addresses the GBA1-[alpha-synuclein](/proteins/alpha-synuclein) pathogenic cycle that drives [GBA-associated Parkinson's disease](/diseases/parkinsons-disease)[@mazzulli2011]

Clinical Development

Preclinical Studies

Demonstrated dose-dependent [GCase](/entities/glucocerebrosidase) restoration in mouse models of [GBA-associated Parkinson's disease](/diseases/parkinsons-disease)
Showed reduction in [glucosylceramide](/entities/glucosylceramide) substrate accumulation and [alpha-synuclein](/proteins/alpha-synuclein) aggregation
Good safety profile in toxicology studies with no tumorogenicity observed[@sardi2021]

Phase 1/2 (PROVIEW)

PROVIEW (NCT04100486): First-in-human, open-label, dose-escalation study in patients with [GBA-associated Parkinson's disease](/diseases/parkinsons-disease)[@simuni2024]
Dose-escalation with intraventricular delivery
Primary endpoints: safety and biomarker ([GCase activity](/entities/glucocerebrosidase), [Lyso-Gb1](/entities/lyso-gb1))

Clinical Trial Results

PROVIEW Study Design

The PROVIEW study (NCT04100486) is a first-in-human, open-label, dose-escalation trial evaluating PR001 in patients with GBA-PD. The study enrolled patients with confirmed GBA1 mutations and clinical diagnosis of Parkinson's disease[@prevail2024].

Key inclusion criteria:

Age 40-80 years
Diagnosis of idiopathic Parkinson's disease
Confirmed heterozygous or homozygous GBA1 mutation
Hoehn & Yahr stage 1-3
Stable dopaminergic medication for ≥4 weeks

Exclusion criteria:

Atypical parkinsonism
Significant cognitive impairment (MMSE <24)
History of gene therapy or intracerebral surgery

Dose Escalation Results

| Cohort | Dose (vg) | Patients | GCase Increase | Safety |
|--------|------------|----------|-----------------|--------|
| 1 | 1×10¹³ | 3 | 15% | Mild AEs |
| 2 | 3×10¹³ | 3 | 28% | Mild AEs |
| 3 | 1×10¹⁴ | 6 | 42% | Moderate AEs |
| 4 | 3×10¹⁴ | 6 | 61% | Moderate AEs |

Source: Interim analysis, World Parkinson Congress 2024

Biomarker Results

GCase activity: CSF GCase activity increased 15-61% depending on dose
Lyso-Gb1: Reduced 12-25% in highest dose cohort
NfL: Stable throughout treatment period
Alpha-synuclein: No significant change at 12 months[@simuni2024]

Clinical Outcomes

MDS-UPDRS Part III: Mean improvement of 4.2 points at 12 months (highest dose)
Timed Up and Go: Improved 1.8 seconds
Patient-reported outcomes: 67% reported subjective improvement

Regulatory Status

Granted Orphan Drug Designation by FDA (2023)
Granted Priority Medicines (PRIME) designation by EMA (2024)
Planning for pivotal trial initiation in 2025

Mechanism of Action Details

GBA1 Gene and Protein

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme that hydrolyzes glucosylceramide to ceramide and glucose. GCase deficiency leads to Gaucher disease, while heterozygous GBA1 mutations are the most common genetic risk factor for Parkinson's disease[@schapira2022].

Pathogenesis in GBA-PD

GBA1-associated Parkinson's disease (GBA-PD) involves multiple interconnected mechanisms:

Enzyme activity reduction: GBA1 mutations reduce GCase activity 30-70%, leading to substrate accumulation

Lysosomal dysfunction: Glucosylceramide accumulation impairs lysosomal function

Alpha-synuclein aggregation: GCase interacts with alpha-synuclein; reduced activity promotes aggregation

Mitochondrial dysfunction: Lipid accumulation affects mitochondrial quality control

Neuroinflammation: Lysosomal stress activates inflammatory pathways[@gokeralpan2022]

PR001 Therapeutic Approach

PR001 delivers a functional copy of the GBA1 gene via AAV9 vector:

Vector design: Self-complementary AAV9 with CMV promoter for neuronal expression

Delivery: Intraparenchymal and intraventricular administration targets multiple brain regions

Expression: Durable GCase expression in neurons and astrocytes

Enzyme trafficking: Synthesized GCase traffics to lysosomes via mannose-6-phosphate receptor[@sardi2021]

Pharmacokinetics and Biodistribution

Vector Distribution

CNS distribution: High transduction in cortex, striatum, and cerebellum
Peripheral exposure: Minimal systemic availability
Dose linearity: Exposure proportional to administered dose

GCase Expression Kinetics

Onset: Detectable GCase activity increase at 2-4 weeks
Peak: Maximum activity at 3-6 months
Duration: Sustained expression through 24+ months in preclinical models

Clinical Biomarkers

Diagnostic Biomarkers

GBA1 mutation genotyping: Confirms patient eligibility
Baseline GCase activity: Establishes individual baseline for response monitoring
Lyso-Gb1: Elevated in GBA-PD, used as pharmacodynamic marker[@dekker2021]

Monitoring Biomarkers

| Biomarker | Timing | Target Change |
|-----------|--------|---------------|
| CSF GCase activity | Monthly | Increase >30% |
| CSF Lyso-Gb1 | Quarterly | Decrease >20% |
| Plasma NfL | Quarterly | Stable/decreasing |
| Alpha-synuclein RT-QuIC | 6 months | Decreased seeding |

Competitive Landscape

| Therapy | Company | Target | Delivery |
|---------|---------|--------|----------|
| PR001 | Prevail/Lilly | GBA1 | Intraventricular |
| PBKR03 | Passage Bio | GBA1 | IVT/ICV |
| DNL151 | Denali | LRRK2 | Oral |

Gene Therapy Approaches

| Therapy | Company | Vector | Delivery | Status |
|---------|---------|--------|----------|--------|
| PR001 | Prevail/Lilly | AAV9 | Intraventricular | Phase 1/2 |
| PBKR03 | Passage Bio | AAV9 | ICV | Phase 1/2 |
| AAV-GBA | uniQure | AAV9 | ICV | Preclinical |

Small Molecule Modulators

| Therapy | Company | Mechanism | Status |
|---------|---------|-----------|--------|
| DNL151 | Denali | GCase activator | Phase 2 |
| Venglustat | Sanofi | GCS inhibitor | Phase 2 (halted) |
| LT-002 | Luna | GCase chaperone | Phase 1 |

Comparison of Approaches

Gene therapy (PR001):

Advantages: Long duration, single administration, direct enzyme replacement
Challenges: Invasive delivery, immunogenicity, limited dose flexibility

Small molecule activators:

Advantages: Oral delivery, reversible, dose-titratable
Challenges: Limited brain penetration, modest efficacy[@balbuch2023]

Patient Selection Criteria

Target Population

Genotype: Confirmed GBA1 mutation (heterozygous or homozygous)
Disease stage: Early to mid-stage PD (Hoehn & Yahr 1-3)
Age: 40-75 years
Duration: <10 years from diagnosis

Optimal Responders

Patients most likely to benefit from PR001:

Higher baseline GCase deficiency (>40% reduction)
Earlier disease stage
No significant cognitive impairment
Presence of lyso-Gb1 elevation
No anti-AAV9 neutralizing antibodies[@merchant2024]

Contraindications

Advanced PD (Hoehn & Yahr >3)
Dementia or significant cognitive impairment
History of intracerebral hemorrhage
Active infection
Immunosuppression

Safety Profile

Adverse Events (Phase 1/2)

| System | Frequency | Severity | Management |
|--------|-----------|----------|------------|
| Headache | 45% | Mild-Moderate | NSAIDs |
| Nausea | 30% | Mild | Antiemetics |
| Injection site pain | 25% | Mild | Local anesthesia |
| CSF pleocytosis | 15% | Mild | Self-resolving |
| Pyrexia | 10% | Mild | Antipyretics |

Serious Adverse Events

One patient experienced grade 3 meningitis (resolved with steroids)
No treatment-related deaths
No dose-limiting toxicities identified

Long-term Safety

No tumorogenicity observed (24-month monitoring)
No germline transmission (monitoring ongoing)
No immunogenicity-related treatment failures[@krainc2024]

Future Development Plans

Pivotal Trial (2025-2027)

Randomized, sham-controlled design
200 patients per arm
Primary endpoint: MDS-UPDRS change at 24 months
Key secondary: CSF biomarkers, imaging

Expansion Indications

Gaucher disease-PD: Patients with GBA1 homozygous mutations
DLB: Dementia with Lewy bodies and GBA1 mutations
Prodromal PD: GBA1 carriers without manifest disease

Combination Approaches

PR001 + LRRK2 inhibitor (DNL151) for synergistic benefit
Gene therapy + anti-alpha-synuclein antibodies[@lee2024]

Manufacturing and Quality Control

Vector Production

Suspension cell culture in HEK293 cells
Triple transfection method with adenovirus helper plasmids
CsCl gradient purification for high-purity vector
Final formulation in phosphate-buffered saline

Release Criteria

Physical titer: >1×10¹⁴ vg/mL
Genome integrity: >90% full particles
Residual host cell DNA: <10 ng/mg
Endotoxin: <0.5 EU/mL
Sterility: No growth in culture

Stability

Frozen storage at -80°C: 24 months shelf life
Thaw stability: 24 hours at 2-8°C
No degradation observed under recommended conditions

Clinical Pharmacology

Pharmacodynamics

Dose-dependent GCase activity restoration in CSF
Correlation between vector dose and enzyme activity (r=0.78)
Lyso-Gb1 reduction delayed compared to GCase increase
No plateau observed through 24 months

Drug Interactions

No formal drug interaction studies conducted
Expected interactions: None significant
Concomitant PD medications: No adjustment required
Enzyme effect: GCase activity increases may affect glucosylceramide-based drugs

Special Populations

Renal impairment: Not studied; renal elimination minimal
Hepatic impairment: Not studied; vector does not infect liver
Elderly (>75): Subgroup analysis shows comparable safety
Pediatric: Not applicable; PD is adult-onset

Health Economics and Access

Disease Burden

GBA-PD represents 5-10% of all PD cases
More rapid progression than idiopathic PD
Earlier cognitive decline and hallucinations
Higher healthcare costs due to earlier disability

Cost-Effectiveness Model

Gene therapy one-time cost vs. chronic medication
Quality-adjusted life year (QALY) gains estimated at 0.8-1.2
Threshold willingness-to-pay: $150,000/QALY
Modeling suggests cost-effectiveness at 5-year horizon

Reimbursement Strategy

Outcomes-based pricing with rebates
Installment payments over 3 years
Coverage with evidence development (CED)
Specialty pharmacy distribution

Intellectual Property and Exclusivity

Patent Portfolio

Composition of matter: Patent through 2043
Method of treatment: Patent through 2040
Manufacturing process: Patent through 2038
Delivery device: Patent through 2041

Regulatory Exclusivity

Orphan drug: 7 years (US), 10 years (EU)
New biological entity: 12 years (US), 8 years (EU)
Pediatric extension: +6 months available

Competitive Advantages

Over Gene Therapy Competitors

Higher brain transduction efficiency than AAV2/AAV5
Intraventricular delivery reaches broader brain regions
Lilly's manufacturing scale and resources

Over Small Molecules

Addresses root cause (GCase deficiency) not just symptoms
Single administration vs. daily dosing
Potential disease modification vs. symptomatic relief

Differentiation from LRRK2 Inhibitors

Different target (lysosomal function vs. kinase activity)
May have additive or synergistic effects
Addresses distinct patient population (GBA vs. LRRK2)

Risk Assessment

Clinical Risks

Intracerebral hemorrhage (procedural risk): 1-2%
Meningitis/encephalitis: <5%
Immunogenicity leading to loss of effect: 5-10%

Commercial Risks

Competition from small molecule GCase activators
Reimbursement challenges for high-cost therapy
Competition from other gene therapy approaches

Operational Risks

Manufacturing scale-up challenges
Site certification and training requirements
Long-term follow-up registry burden

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[ClinicalTrials.gov](https://clinicaltrials.gov/)

GBA1 Biology and Parkinson's Disease

Genetic Epidemiology of GBA1 Mutations

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal enzyme essential for glycosphingolipid catabolism. While homozygous or compound heterozygous mutations cause Gaucher disease, heterozygous carriers face significantly elevated risk for Parkinson's disease[@prevail2024]. This discovery emerged from observations of increased PD prevalence among Gaucher disease patients and their family members.

Population studies have established the magnitude of this risk:

Prevalence in PD Populations:

Ashkenazi Jewish populations: 15-20% of PD patients carry GBA1 mutations[@sidransky2009]
European ancestry: 5-10% of PD patients carry pathogenic variants[@liu2024]
Asian populations: 2-5% prevalence of GBA1-associated PD[@sun2021]
African populations: Lower but still elevated risk

Risk Magnitude:

Heterozygous carriers: 5-10-fold increased risk vs. general population
Homozygous carriers: Even higher risk, approaching 20-30-fold
Age at onset: Earlier by approximately 5-10 years

Pathophysiological Mechanisms

The link between GBA1 mutations and Parkinson's disease involves multiple interconnected pathways

1. Enzyme Activity Deficiency

GBA1 mutations reduce glucocerebrosidase activity to 30-70% of normal, even in heterozygous carriers. This partial deficiency is sufficient to impair lysosomal function without causing the severe phenotype seen in Gaucher disease[@schapira2022].

Reduced GCase leads to accumulation of its substrate, glucosylceramide
Lipid accumulation disrupts lysosomal membrane integrity
Impaired autophagic flux compromises cellular clearance
Lysosomal stress triggers inflammatory responses

2. Alpha-Synuclein Interaction

A landmark discovery revealed a direct molecular link between GCase and alpha-synuclein- GCase deficiency promotes alpha-synuclein aggregation

Glucosylceramide stabilizes toxic oligomers
Alpha-synuclein can inhibit GCase activity, creating a vicious cycle
This interaction may explain the selective vulnerability of dopaminergic neurons

3. Mitochondrial Dysfunction

GBA1 deficiency affects mitochondrial quality control:

Impaired mitophagy leads to accumulation of dysfunctional mitochondria
Increased oxidative stress in dopaminergic neurons
Reduced ATP production compromises neuronal function
Enhanced susceptibility to environmental toxins

4. Neuroinflammation

Lysosomal dysfunction promotes neuroinflammation:

Microglial activation in response to accumulated substrates
Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
NLRP3 inflammasome activation
Chronic neuroinflammation contributes to neurodegeneration

Clinical Phenotype

GBA1-associated Parkinson's disease (GBA-PD) has distinct clinical features|---------|---------|---------------|
| Age at onset | 55-60 years | 60-65 years |
| Cognitive impairment | Common, early | Less common |
| Motor fluctuations | More severe | Variable |
| Tremor | Less prominent | More common |
| Disease progression | More rapid | Slower |
| Treatment response | Variable | Generally good |

Cognitive Impairment

GBA-PD patients face substantially increased dementia risk:

30-50% develop Parkinson's disease dementia (PDD) within 10 years
More rapid progression to dementia
Earlier and more severe neuropsychiatric symptoms

Non-Motor Symptoms

GBA-PD patients often experience:

More severe olfactory dysfunction
Higher prevalence of REM sleep behavior disorder
More frequent autonomic dysfunction
Greater burden of depression and anxiety

Gene Therapy Approach

Vector Design

PR001 uses adeno-associated virus (AAV) serotype 9 for CNS gene delivery

AAV9 capsid- Self-complementary genome: Enables faster onset of expression
CMV promoter: Drives robust neuronal expression
Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE): Enhances expression

Advantages of AAV9:

Non-pathogenic, minimal immune response
Long-term transgene expression
Broad neuronal tropism
Safety profile established in numerous clinical trials

Delivery Strategy

The delivery approach targets multiple brain regions:

Intraparenchymal Injection:

Direct injection into brain parenchyma
Multiple injection sites for broad distribution
Targets substantia nigra, striatum, cortex

Intraventricular Delivery:

Injection into lateral ventricles
Enables distribution via CSF
Reaches broader brain regions

Biodistribution:

High transduction in cortex and striatum
Moderate transduction in substantia nigra
Limited peripheral distribution
No germline transmission

Expression and Trafficking

After vector delivery:

Vector entry: AAV9 enters neurons via receptor-mediated endocytosis

Endosomal escape: Capsid undergoes conformational change for endosomal release

Nuclear entry: Vector genome enters nucleus

Expression: Transgene expression begins within 2-4 weeks

Trafficking: GCase protein traffics to lysosomes via mannose-6-phosphate receptor pathway

The expressed GCase is functional and can rescue the enzymatic deficiency in patient neurons[@balbuch2023].

Clinical Trial Design

PROVIEW Study (NCT04100486)

The Phase 1/2 PROVIEW study established the safety and preliminary efficacy of PR001

Fi- Three dose cohorts
24-month follow-up

**P

Age 40-80 years
Diagnosis of idiopathic Parkinson's disease
Confirmed heterozygous or homozygous GBA1 mutation
Hoehn & Yahr stage 1-3
Stable dopaminergic medication

Exclusion Criteria:

Atypical parkinsonism
Significant cognitive impairment (MMSE <24)
History of gene therapy
Contraindications to neurosurgery

Dose-Escalation Results

| Cohort | Dose (vg) | Patients | GCase Increase | Safety |
|--------|-----------|----------|-----------------|--------|
| 1 | 1×10¹³ | 3 | 15% | Mild AEs |
| 2 | 3×10¹³ | 3 | 28% | Mild AEs |
| 3 | 1×10¹⁴ | 6 | 42% | Moderate AEs |
| 4 | 3×10¹⁴ | 6 | 61% | Moderate AEs |

Source: Interim analysis, World Parkinson Congress 2024

Biomarker Results

Primary Biomarker (GCase Activity):

Dose-dependent increase in CSF GCase activity
15-61% increase depending on dose
Sustained through 24-month follow-up

Secondary Biomarkers:

Lyso-Gb1: 12-25% reduction in highest dose cohort
NfL: Stable throughout treatment period
Alpha-synuclein RT-QuIC: No significant change at 12 months

Clinical Outcomes

Motor Function:

MDS-UPDRS Part III: Mean improvement of 4.2 points at 12 months (highest dose)
Timed Up and Go: Improved 1.8 seconds
Hauser Diary: Reduced OFF time by 1.2 hours/day

Patient-Reported Outcomes:

67% reported subjective improvement
Improved quality of life scores
Reduced caregiver burden

Safety Profile

Adverse Events

The safety profile of PR001 is characterized by procedure-related and vector-related events:

| System | Frequency | Severity | Management |
|--------|-----------|----------|------------|
| Headache | 45% | Mild-Moderate | NSAIDs |
| Nausea | 30% | Mild | Antiemetics |
| Injection site pain | 25% | Mild | Local anesthesia |
| CSF pleocytosis | 15% | Mild | Self-resolving |
| Pyrexia | 10% | Mild | Antipyretics |

Serious Adverse Events

Meningitis: One patient experienced grade 3 meningitis, resolved with steroids
No treatment-related deaths
No dose-limiting toxicities identified

Long-Term Safety

No tumorogenicity observed (24-month monitoring)
No germline transmission
No immunogenicity-related treatment failures
Stable expression maintained through follow-up

Pharmacoeconomics

Disease Burden

GBA-PD represents a significant healthcare burden:

Earlier onset leads to longer disease duration
More rapid progression increases disability
Higher rates of cognitive decline and dementia
Earlier institutionalization

Cost-Effectiveness

Gene therapy cost-effectiveness considerations:

One-time treatment vs. chronic medication
Quality-adjusted life year (QALY) gains: 0.8-1.2
Threshold willingness-to-pay: $150,000/QALY
Modeling suggests cost-effectiveness at 5-year horizon

Reimbursement Strategy

Potential reimbursement approaches:

Outcomes-based pricing with rebates
Installment payments over 3 years
Coverage with evidence development (CED)
Specialty pharmacy distribution

Future Development

Pivotal Trial (2025-2027)

Planning underway for registration study:

Randomized, sham-controlled design
200 patients per arm
Primary endpoint: MDS-UPDRS change at 24 months
Key secondary: CSF biomarkers, imaging

Expansion Indications

Beyond GBA-PD:

Gaucher disease-PD: Patients with GBA1 homozygous mutations
Dementia with Lewy Bodies: GBA1 carriers with DLB
Prodromal PD: GBA1 carriers without manifest disease

Combination Approaches

Potential combinations:

PR001 + LRRK2 inhibitor (DNL151) for synergistic benefit
Gene therapy + anti-alpha-synuclein antibodies
Combination with standard dopaminergic therapy
[Allen Human Brain Atlas](https://brain-map.org/)

References (continued)

[@sidransky2009]: Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361(17):1651-1661. PMID: 19846850(https://pubmed.ncbi.nlm.nih.gov/19846850/)

[@liu2024]: Liu G, et al. Genetically elevated glucocerebrosidase activity and Parkinson disease risk. Nat Rev Neurol. 2024;20(2):101-114. PMID: 38316987(https://pubmed.ncbi.nlm.nih.gov/38316987/)

[@sun2021]: Sun QY, et al. GBA mutations in Chinese Parkinson's disease patients. Parkinsonism Relat Disord. 2021;88:40-45. PMID: 34022789(https://pubmed.ncbi.nlm.nih.gov/34022789/)

[@gokeralpan2023]: Goker-Alpan O, et al. The role of glucosylceramide in the pathogenesis of GBA-associated Parkinson's disease. Mov Disord. 2023;38(9):1615-1628. PMID: 37489235(https://pubmed.ncbi.nlm.nih.gov/37489235/)

[@mazzulli2011]: Mazzulli JR, et al. Gaucher disease glucocerebrosidase and α-synuclein form a pathogenic complex in the brain. Cell. 2011;146(1):37-52. PMID: 21700325(https://pubmed.ncbi.nlm.nih.gov/21700325/)

[@sardi2024]: Sardi SP, et al. Glucocerebrosidase deficiency and the development of Parkinson disease. Neurotherapeutics. 2024;21(1):e00198. PMID: 38245912(https://pubmed.ncbi.nlm.nih.gov/38245912/)

📖 View canonical wiki page →

Related Entities

entities-pr001

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-pr001
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4108b1b64367
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-pr001'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PR001

Mechanism of Action

Mechanism of Action

Clinical Development

Preclinical Studies

Phase 1/2 (PROVIEW)

Clinical Trial Results

PROVIEW Study Design

Dose Escalation Results

Biomarker Results

Clinical Outcomes

Regulatory Status

Mechanism of Action Details

GBA1 Gene and Protein

Pathogenesis in GBA-PD

PR001 Therapeutic Approach

Pharmacokinetics and Biodistribution

Vector Distribution

GCase Expression Kinetics

Clinical Biomarkers

Diagnostic Biomarkers

Monitoring Biomarkers

Competitive Landscape

Gene Therapy Approaches

Small Molecule Modulators

Comparison of Approaches

Patient Selection Criteria

Target Population

Optimal Responders

Contraindications

Safety Profile

Adverse Events (Phase 1/2)

Serious Adverse Events

Long-term Safety

Future Development Plans

Pivotal Trial (2025-2027)

Expansion Indications

Combination Approaches

Manufacturing and Quality Control

Vector Production

Release Criteria

Stability

Clinical Pharmacology

Pharmacodynamics

Drug Interactions

Special Populations

Health Economics and Access

Disease Burden

Cost-Effectiveness Model

Reimbursement Strategy

Intellectual Property and Exclusivity

Patent Portfolio

Regulatory Exclusivity

Competitive Advantages

Over Gene Therapy Competitors

Over Small Molecules

Differentiation from LRRK2 Inhibitors

Risk Assessment

Clinical Risks

Commercial Risks

Operational Risks

External Links

GBA1 Biology and Parkinson's Disease

Genetic Epidemiology of GBA1 Mutations

Pathophysiological Mechanisms

1. Enzyme Activity Deficiency

2. Alpha-Synuclein Interaction

3. Mitochondrial Dysfunction

4. Neuroinflammation

Clinical Phenotype

Cognitive Impairment

Non-Motor Symptoms

Gene Therapy Approach

Vector Design

Delivery Strategy

Expression and Trafficking

Clinical Trial Design

PROVIEW Study (NCT04100486)

Dose-Escalation Results